Washington – Federal officials approved another common version Abortion tablets of mifepristonregulatory formality, which quickly caused a rollback from Groups against abortion And politicians have leveled off the administration of Trump.
The manufacturer of drugs Evita Solutions has announced on his web site that Product control control Signed in an inexpensive form tabletWhich is approved for the end of pregnancy for 10 weeks.
Students for the whole life who are opposed to abortions, in a statement on Thursday, called the approval “a spot on Trump's presidency and another sign that a deep state should go to FDA.”
Senator -Republican Josh Hawie from Missouri also criticized this step in the post about X, saying: “I lost confidence in the leadership in FDA.”
Criticism comes as the main health officials of President Donald Trump, including the Minister of Health Robert F. Kennedy -MostHe is faced with growing pressure from opponents of abortion to reassess Mifepristone, which was approved 25 years ago and was repeatedly considered the safe and effective scientists of FDA.
In a letter to General -Republican Lawyers last month Kennedy and Commissioner FDA Dr. Marty Makari He promised to conduct a complete overview of the safety of the drug.
FDA approved the original version of Mifepristone in 2000 and gradually weakened access over time. This included the approval of the first common tablet from the manufacturer of Genbiopro medicines, in 2019.
In 2021, FDA under the President of the Democratic Party Joe Biden Allowed online subsidence And the delivery of the drug by mail, significantly expanding access. Since then, opponents of abortion have fought with changes.
The approval of general drugs, as a rule, is the process of a company in FDA, and numerous versions of the imitation are usually approved after the patent expiration for the original medicine. In most cases, drug manufacturers should only show that they coincide with drugs and a formula developed by the original drug manufacturer.
FDA usually approves such applications for 10 months. But the submission of documents placed on the web file FDA shows that Evita Solutions has applied to the Mifepristone market four years ago.
The company did not immediately respond to comments.
On her website, Evita claims that she “believes that all people should have access to safe, affordable, high-quality, effective and compassionate abortion”.
The approval of the second genenic is unlikely to affect Access to tabletsWhich is usually taken using another drug, a mizstol. The combination is approximately two -thirds of all US abortions. Mifepristone expands the cervix and blocks the hormone progesterone, while the Misoprostol makes the uterus of cramps and contract.
Access to Mifepriston limited In large areas of the country from state laws that prohibit abortion, including abortion of drugs, or impose individual restrictions on the use of the drug. These laws are subject to a row The ongoing trials who make their way through Legal system.
Restrictions on tablets are not supported by most large medical societies, including the American Medical Association.
___
The Associated Press Health and Science Department receives support from the Group of Science and the Educational Institute of the Medical Institute of Howard Hughes and the Robert Wood Johnson Foundation. AP bears sole responsibility for all content.
